{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:18:46Z","timestamp":1772705926555,"version":"3.50.1"},"reference-count":66,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Emerging Drugs"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1517\/14728214.2013.750294","type":"journal-article","created":{"date-parts":[[2012,11,26]],"date-time":"2012-11-26T07:40:33Z","timestamp":1353915633000},"page":"87-95","source":"Crossref","is-referenced-by-count":23,"title":["Emerging drugs for focal epilepsy"],"prefix":"10.1517","volume":"18","author":[{"given":"Marco","family":"Mula","sequence":"first","affiliation":[{"name":"Amedeo Avogadro University, University Hospital Maggiore della Carit\u00e0, Division of Neurology","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2012,11,26]]},"reference":[{"key":"e_1_3_1_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822cfc90"},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2007.12.019"},{"issue":"12","key":"e_1_3_1_5_1","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/j.1528-1167.2007.01251.x","article-title":"Estimating the cost of epilepsy in Europe: a review with economic modeling","volume":"48","author":"Pugliatti M","year":"2007","unstructured":"Pugliatti M, Beghi E, Forsgren L, Estimating the cost of epilepsy in Europe: a review with economic modeling. Epilepsia 2007;48(12):2224-33","journal-title":"Epilepsia"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152409788452063"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"key":"e_1_3_1_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02299.x"},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1430"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.010"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01526.x"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02164.x"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7511.2007.00156.x"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.57.4.13"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.09.012"},{"issue":"17","key":"e_1_3_1_16_1","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1523\/JNEUROSCI.17-17-06639.1997","article-title":"Prolonged sodium channel inactivation contributes to dendritic action potential attenuation in hippocampal pyramidal neurons","volume":"17","author":"Jung HY","year":"1997","unstructured":"Jung HY, Mickus T, Spruston N. Prolonged sodium channel inactivation contributes to dendritic action potential attenuation in hippocampal pyramidal neurons. J Neurosci 1997;17(17):6639-46","journal-title":"J Neurosci"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/pr.55.4.8"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2004.03625.x"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00051-4"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(00)01629-5"},{"key":"e_1_3_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2008.10.003"},{"issue":"3","key":"e_1_3_1_22_1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0022-3565(24)39009-3","article-title":"Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin","volume":"295","author":"Dooley DJ","year":"2000","unstructured":"Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295(3):1086-93","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2004.10.002"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(03)00248-X"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/11205950-000000000-00000"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200115050-00001"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.2147\/CPAA.S15369"},{"key":"e_1_3_1_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1625"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2003.08.006"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0028-3908(00)00112-X"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-11.2.56"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1535-7597.2005.05101.x"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03242.x"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)02439-7"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-0102(00)00127-9"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.09.001"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00324.x"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01486.x"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(00)00170-4"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01182.x"},{"key":"e_1_3_1_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03109.x"},{"key":"e_1_3_1_42_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182635735"},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318254473a"},{"issue":"4","key":"e_1_3_1_44_1","first-page":"263","article-title":"Perampanel Study 207: long-term open-label evaluation in patients with epilepsy","volume":"126","author":"Rektor I","year":"2012","unstructured":"Rektor I, Krauss GL, Bar M, Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012;126(4):263-9","journal-title":"Acta Neurol Scand"},{"key":"e_1_3_1_45_1","article-title":"Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","author":"Krauss GL","year":"2012","unstructured":"Krauss GL, Perucca E, Ben-Menachem E, Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia 2012; Epub ahead of print","journal-title":"Epilepsia"},{"key":"e_1_3_1_46_1","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","author":"French JA","year":"2012","unstructured":"French JA, Krauss GL, Steinhoff BJ, Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 2012; [Epub ahead of print]","journal-title":"Epilepsia"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.001"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.10.008"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S25099"},{"key":"e_1_3_1_50_1","unstructured":"Auberson YP. BGG492 a competitive ampa\/kainate antagonist for the treatment of epilepsy. 2\u00e9mes Journe\u00e9es Scientifiques du M\u00e9dicament; Grenoble; 2012. p. 9"},{"key":"e_1_3_1_51_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.705277"},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.12.004"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02366.x"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e318198317b"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-011-0039-z"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00590.x"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2008.05.007"},{"key":"e_1_3_1_58_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161207780163006"},{"key":"e_1_3_1_59_1","article-title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial","author":"Van Paesschen W","year":"2012","unstructured":"Van Paesschen W, Hirsch E, Johnson M, Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2012; [Epub ahead of print]","journal-title":"Epilepsia"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7f7f"},{"key":"e_1_3_1_61_1","unstructured":"Pharmaprojects. Pharmaprojects - copyright to Citeline Drug Intelligence (an informa business). 2012"},{"issue":"6","key":"e_1_3_1_62_1","first-page":"921","article-title":"DP-VPA D-Pharm","volume":"3","author":"Labiner DM","year":"2002","unstructured":"Labiner DM. DP-VPA D-Pharm. Curr Opin Investig Drugs 2002;3(6):921-3","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_1_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2007.10.025"},{"key":"e_1_3_1_64_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000261917.83337.db"},{"key":"e_1_3_1_65_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923020-00003"},{"key":"e_1_3_1_66_1","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2009.0238"},{"key":"e_1_3_1_67_1","doi-asserted-by":"publisher","DOI":"10.2217\/npy.11.29"},{"key":"e_1_3_1_68_1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1177391X0800200001","article-title":"Modifications of antiepileptic drugs for improved tolerability and efficacy","volume":"2","author":"Landmark CJ","year":"2008","unstructured":"Landmark CJ, Johannessen SI. Modifications of antiepileptic drugs for improved tolerability and efficacy. Perspect Medicin Chem 2008;2:21-39","journal-title":"Perspect Medicin Chem"}],"container-title":["Expert Opinion on Emerging Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14728214.2013.750294","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T09:28:27Z","timestamp":1772702907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14728214.2013.750294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,26]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1517\/14728214.2013.750294"],"URL":"https:\/\/doi.org\/10.1517\/14728214.2013.750294","relation":{},"ISSN":["1472-8214","1744-7623"],"issn-type":[{"value":"1472-8214","type":"print"},{"value":"1744-7623","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,26]]}}}